Document is current
Any future updates will be listed below
-
Authors
Henriksen, Kristine https://orcid.org/0000-0001-8932-5933
Rufer, Chantal https://orcid.org/0000-0002-7314-6364
Title, Alexandra C. https://orcid.org/0009-0004-9289-0836
Jawurek, Sayro https://orcid.org/0009-0002-4821-5935
Hartmann, Bolette https://orcid.org/0000-0001-8509-2036
Holst, Jens J. https://orcid.org/0000-0001-6853-3805
Knop, Filip K. https://orcid.org/0000-0002-2495-5034
Yesildag, Burcak https://orcid.org/0000-0002-5638-8708
Størling, Joachim https://orcid.org/0000-0002-7529-4264
-
Funding
Funding for this research was provided by:
Poul and Erna Sehested-Hansen Foundation
Leona M. and Harry B. Helmsley Charitable Trust (1912-03551)
Copenhagen University
- License Information
-
More Information
Article History
Received: 28 August 2024
Accepted: 11 February 2025
First Online: 15 May 2025
Acknowledgements
: The authors gratefully acknowledge organ donors and the next of kin of organ donors, without whom this research would not be possible. The authors thank R. Gerwig from Steno Diabetes Center Copenhagen and L. B. Albæk from the University of Copenhagen for the technical support with the chemokine and somatostatin measurements, respectively.
: The datasets generated and analysed during the study are available from the corresponding author upon reasonable request.
: Open access funding provided by Copenhagen University. This paper represents independent research supported by funding from The Leona M. and Harry B. Helmsley Charitable Trust (grant no. 1912-03551) and the Poul and Erna Sehested-Hansen Foundation. No funders were involved in the study design, data collection, analysis, interpretation, writing or decision to submit the article for publication.
: CR, ACT, SJ and BY are employees of InSphero. BH is a co-founder of Bainan Biotech. JJH has served on scientific advisory panels for and/or has received speaker honoraria from Novo Nordisk and MSD/Merck, is co-founder and board member of Antag Therapeutics, and is co-founder of Bainan Biotech. FKK has served on scientific advisory panels and/or been part of speaker’s bureaus for, served as a consultant to, and/or received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Sanofi, ShouTi, Zealand Pharma and Zucara. FKK is a co-founder of and minority shareholder in Antag Therapeutics, owns stocks in Eli Lilly, Novo Nordisk and Zealand Pharma, and has been employed by Novo Nordisk since 1 December 2023. JS owns stocks in Novo Nordisk A/S. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.
: KH, FKK and JS conceptualised the study. KH, BY and JS designed the experiments. KH, CR, SJ, ACT, BH, JJH and BY contributed to the data acquisition and analysis. KH wrote the initial manuscript draft and JS provided comments. All authors provided critical scientific input to the manuscript and approved the final version. JS is the guarantor of this work.
